Analysts expect Ascendis Pharma A/S to report revenue of 386.59 M for Q3 26, against a range of 364.42 M to 408.76 M. The most recent reported quarter, Q2 26, came in at 387.48 M, a 5.1% beat against the 368.66 M consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 64.39 M | 180.04 M | 109.22 M | 186.18 M | 250.69 M | 290.69 M | 284.92 M | 387.48 M | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | 77.64 M | 126.93 M | 102.68 M | 168.38 M | 260.43 M | 311.94 M | 340.30 M | 395.57 M | 408.76 M | 521.64 M | 489.20 M | 622.63 M | 751.03 M | 935.31 M | 546.50 M | 596.90 M | ||||||||||
| Low Estimate | 71.50 M | 106.86 M | 93.24 M | 152.07 M | 215.37 M | 292.48 M | 308.26 M | 341.76 M | 364.42 M | 469.97 M | 443.45 M | 537.75 M | 641.49 M | 823.61 M | 509.14 M | 541.38 M | ||||||||||
| Consensus Estimate | 74.57 M | 116.90 M | 97.96 M | 160.22 M | 237.90 M | 302.21 M | 324.28 M | 368.66 M | 386.59 M | 495.81 M | 466.33 M | 580.19 M | 696.26 M | 879.46 M | 527.82 M | 569.14 M |
Analysts expect Ascendis Pharma A/S to report earnings per share of 0.94 for Q3 26, against a range of 0.89 to 0.99. The most recent reported quarter, Q2 26, came in at 3.23, a 93.4% beat against the 1.67 consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -1.92 | -0.66 | -1.71 | -0.97 | -1.17 | -0.65 | 11.26 | 3.23 | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | -1.63 | -0.91 | -1.55 | -1.46 | -0.27 | -0.08 | 0.19 | 1.76 | 0.99 | 1.29 | 2.19 | 2.58 | 0.81 | 0.99 | 5.98 | 4.52 | ||||||||||
| Low Estimate | -1.75 | -1.01 | -1.75 | -1.68 | -0.29 | -0.10 | 0.17 | 1.58 | 0.89 | 1.07 | 2.03 | 2.34 | 0.75 | 0.91 | 4.94 | 3.80 | ||||||||||
| Consensus Estimate | -1.69 | -0.96 | -1.65 | -1.57 | -0.28 | -0.09 | 0.18 | 1.67 | 0.94 | 1.18 | 2.11 | 2.46 | 0.78 | 0.95 | 5.46 | 4.16 |
Pull Wall Street consensus for Ascendis Pharma A/S (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/estimates?ticker=ASND&mode=revenue&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/estimates"
params = {"ticker": "ASND", "mode": "revenue", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/estimates?ticker=ASND&mode=revenue&api_key=YOUR_API_KEY");
const data = await res.json();